New Bench-Top Clinical Chemistry Analyzer Launched By EKF diagnostic GmbH At AACC 2015
Cardiff, UK – 23rd July 2015 – EKF Diagnostics, the global in vitro diagnostics company, announces the international launch of the Altair™ 240 clinical chemistry analyzer at the American Association for Clinical Chemistry’s (AACC) Annual Meeting and Clinical Lab Expo in Atlanta, Ga, 26-30 July. This new bench-top platform represents EKF Diagnostics’ first fully integrated chemistry system designed for the global market. Also on Booth #1018, EKF will highlight the latest additions to its range of Stanbio liquid-stable, LiquiColor® and Liqui-UV® clinical chemistry reagents.
The new Altair™ 240 clinical chemistry analyzer fulfills an international market need for a fully automated bench-top platform supported by the reliable and respected Stanbio Chemistry reagent menu. The fully automated system with LIS bi-directional connectivity is capable of performing up to 480 tests per hour*. In addition to being supported by EKF’s broad menu of Stanbio ready-to-use, bar coded, liquid reagents for routine and special chemistries, the Altair™ 240 also provides the flexibility to configure open channel applications for many esoteric assays.
EKF will expand the international presence of its clinical chemistry range with the Altair™ 240, as its customers have long asked for a cost-effective platform designed with Stanbio Chemistry products in mind. Built on 54 years of clinical chemistry expertise, this new platform enables EKF to offer a cost-effective solution, as either a main or back-up analyzer, to improve productivity in both the hospital and physician office laboratory environments.
“We listened to the needs of our customers and designed the Altair™ 240 to be easy to learn, operate and maintain,” said Albert Blanco, Business Unit Director for EKF’s Central Laboratory Division. “Because it runs on Windows® 7, operators can easily navigate its intuitive, touch screen menu. Features such as the capability to use bar coded, primary sample tubes, auto-rerun, auto-dilution and STAT interruption, all function to maximize the system’s overall efficiency.”
Also on Booth# 1018
EKF will also discuss the latest additions to its Stanbio clinical chemistry range, all designed for maximum stability and ease of use. This range includes a large selection of clinical chemistry assays, controls and calibrators, which are fully compatible with most major brand open channel chemistry analyzers. A notable addition is the Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor® test; a new diabetes biomarker test that provides a 2-3 week indicator of average blood glucose.
EKF will also be highlighting two of its point-of-care (POC) hemoglobin analyzers at AACC 2015 - the DiaSpect Tm and HemoPoint® H2. These deliver quick and laboratory accurate results to aid diagnoses of anemia and associated conditions within a variety of near-patient settings, including hospitals, clinics, blood banks and in challenging field-based conditions.
A hand held device delivering results in <2 seconds, DiaSpect Tm is the world’s fastest hemoglobin measurement system offering laboratory quality performance for anemia screening in all climatic conditions. The HemoPoint® H2 stores over 4000 patient results, and is designed for use in blood banks, clinics and hospitals and provides immediate lab-quality results for both hemoglobin and hematocrit - from one test. Its proprietary “soft load” cuvette holder is designed to minimize contamination of the meter.
In addition, live demonstrations of EKF’s Quo-Lab and Quo-Test HbA1c analyzers, as well as its STAT-Site® M B-HB and Lactate Scout point-of-care analyzers will take place at Booth# 1018 throughout each day of the AACC Clinical Lab Expo.
For more information on EKF Diagnostics and its range of products, please visit www.ekfdiagnostics.com.
(*Double arm functionality yields up to 480 tests per hour)
- ENDS -
NB. To request EKF’s full digital press pack for AACC 2015, please contact: charlotteshaw@ekfdiagnostics.com
Editors’ notes
About EKF Diagnostics - www.ekfdiagnostics.com
EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc., DiaSpect and Selah Genomics brands, specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division, EKF Molecular Diagnostics, focuses on technology used within the development of companion diagnostics, specifically within oncology. EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors.
Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory (Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry reagents. In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes used in reagent development and also provides contract fermentation facilities.
Molecular Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics following the acquisition of UK-based 360 Genomics. EKF Molecular Diagnostics’ technology, PointMan™, is capable of detecting mutant genes from tiny biopsy and blood samples and has recently entered a partnership with the world renowned cancer research center at Massachusetts General Hospital, USA.
EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.
Help employers find you! Check out all the jobs and post your resume.
The new Altair™ 240 clinical chemistry analyzer fulfills an international market need for a fully automated bench-top platform supported by the reliable and respected Stanbio Chemistry reagent menu. The fully automated system with LIS bi-directional connectivity is capable of performing up to 480 tests per hour*. In addition to being supported by EKF’s broad menu of Stanbio ready-to-use, bar coded, liquid reagents for routine and special chemistries, the Altair™ 240 also provides the flexibility to configure open channel applications for many esoteric assays.
EKF will expand the international presence of its clinical chemistry range with the Altair™ 240, as its customers have long asked for a cost-effective platform designed with Stanbio Chemistry products in mind. Built on 54 years of clinical chemistry expertise, this new platform enables EKF to offer a cost-effective solution, as either a main or back-up analyzer, to improve productivity in both the hospital and physician office laboratory environments.
“We listened to the needs of our customers and designed the Altair™ 240 to be easy to learn, operate and maintain,” said Albert Blanco, Business Unit Director for EKF’s Central Laboratory Division. “Because it runs on Windows® 7, operators can easily navigate its intuitive, touch screen menu. Features such as the capability to use bar coded, primary sample tubes, auto-rerun, auto-dilution and STAT interruption, all function to maximize the system’s overall efficiency.”
Also on Booth# 1018
EKF will also discuss the latest additions to its Stanbio clinical chemistry range, all designed for maximum stability and ease of use. This range includes a large selection of clinical chemistry assays, controls and calibrators, which are fully compatible with most major brand open channel chemistry analyzers. A notable addition is the Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor® test; a new diabetes biomarker test that provides a 2-3 week indicator of average blood glucose.
EKF will also be highlighting two of its point-of-care (POC) hemoglobin analyzers at AACC 2015 - the DiaSpect Tm and HemoPoint® H2. These deliver quick and laboratory accurate results to aid diagnoses of anemia and associated conditions within a variety of near-patient settings, including hospitals, clinics, blood banks and in challenging field-based conditions.
A hand held device delivering results in <2 seconds, DiaSpect Tm is the world’s fastest hemoglobin measurement system offering laboratory quality performance for anemia screening in all climatic conditions. The HemoPoint® H2 stores over 4000 patient results, and is designed for use in blood banks, clinics and hospitals and provides immediate lab-quality results for both hemoglobin and hematocrit - from one test. Its proprietary “soft load” cuvette holder is designed to minimize contamination of the meter.
In addition, live demonstrations of EKF’s Quo-Lab and Quo-Test HbA1c analyzers, as well as its STAT-Site® M B-HB and Lactate Scout point-of-care analyzers will take place at Booth# 1018 throughout each day of the AACC Clinical Lab Expo.
For more information on EKF Diagnostics and its range of products, please visit www.ekfdiagnostics.com.
(*Double arm functionality yields up to 480 tests per hour)
- ENDS -
NB. To request EKF’s full digital press pack for AACC 2015, please contact: charlotteshaw@ekfdiagnostics.com
Editors’ notes
About EKF Diagnostics - www.ekfdiagnostics.com
EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc., DiaSpect and Selah Genomics brands, specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division, EKF Molecular Diagnostics, focuses on technology used within the development of companion diagnostics, specifically within oncology. EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors.
Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory (Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry reagents. In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes used in reagent development and also provides contract fermentation facilities.
Molecular Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics following the acquisition of UK-based 360 Genomics. EKF Molecular Diagnostics’ technology, PointMan™, is capable of detecting mutant genes from tiny biopsy and blood samples and has recently entered a partnership with the world renowned cancer research center at Massachusetts General Hospital, USA.
EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.
Help employers find you! Check out all the jobs and post your resume.